Bristol Myers Squibb SWOT Analysis

Bristol Myers Squibb SWOT AnalysisGo Beyond the PreviewAccess the Full Strategic Report Bristol Myers Squibb stands on a strong oncology and immunology portfolio with robust R&D pipelines, but faces patent cliffs, pricing pressure, and regulatory risks that could impact growthour full SWOT unpacks these dynamics with financial context and strategic options. Purchase the complete SWOT analysis to receive a professionally formatted Word report and editable Excel matrix for investor

Potential trade disputes involving key trading partners for Australia and New Zealand could impact raw material costs

while competitive rivalry is intense among global niche players pushing innovation and cost efficiency

Renminbi volatility versus the US dollar and euro—which swung about 6% against the dollar in 2024—raises competitiveness risks for exports and increases costs for imported components and technology licenses

revenue growth was supported by contributions from various service segments

Volatility of energy and packaging costs

The Kraft Group's core sports and entertainment holdings

US defense spending grew 3

cementing their status as a top-tier provider in temperature-controlled logistics and demonstrating a clear strategy for growth and diversification

Partner Metric (2024/25) Delta JV ~25% long‑haul rev

18% unrest

Further solidifying their commitment to cutting-edge technology

7bn that year